RT期刊文章SR电子T1新视Neuromyelitis复发急性严重程度量表(P5.249)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P5.249 VO 84 14补充A首页1 Michael Levy A1莫林粉A1斯文Jarius A1 Friedemann保罗西蒙A1 Orhan Aktas A1 Broadley A1菲利普Cabre A1可能汉A1阿奴雅各A1 Gareth约翰A1玛丽亚雷特A1罗曼Marignier A1一郎中岛美嘉A1杰奎琳宫A1斯文Schippling A1安东尼Traboulsee A1布莱恩Weinshenker A1院长Wingerchuk年2015 UL //www.ez-admanager.com/content/84/14_Supplement/P5.249.abstract AB目的:开发和验证一个客观的规模代表程度的神经功能障碍的急性复发Neuromyelitis视。背景:视Neuromyelitis(动)是一种自身免疫性疾病的中枢神经系统(CNS)不同于多发性硬化症(MS)。它的特点是反复发作的视神经炎(上)和纵向广泛的横向脊髓炎(LETM),这通常导致增量与事件相关的残疾。残疾通常被评为使用扩展残疾严重程度量表(eds)为女士开发试验。然而,eds视力和有限的变化不敏感的患者不能走路。设计/方法:我们设计了一个34分急性复发严重程度量表针对动,命名为动严重程度量表(nmos)重点领域最重要的影响包括1)视力,2)视觉领域,3)电机、4)感觉,5)肠和膀胱、6)脑干功能。我们询问了17个国际专家动审查记录20急性动招生约翰霍普金斯医院评估两分的nmos的可靠性和准确性。结果:nmos基于eds,但修改增加对视力和视觉领域。运动,感觉膀胱和肠/分数稍微修改,脑干分数改为关注NMO-specific postrema和间脑的攻击。nmos正在进行验证; inter-rater reliability will be calculated using Spearman's rank correlation coefficient and the NMOSS will be analyzed for content and predictive validity. CONCLUSIONS: The NMOSS is a new NMO-specific disability scale for future clinical trials. Study Supported by: The Guthy Jackson Charitable FoundationDisclosure: Acorda Therapeutics; Sanofi; Viropharma, Inc.; NeuralStem, Inc.; Shire/Abvie; TerumoBCT Dr. Mealy has nothing to disclose. Dr. Jarius has received research support from Bayer Healthcare and Merck Serono. Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Bayer Schering Pharma, Merck Serono, Biogen Idec, MedImmune, and Novartis., Dr. Aktas has received personal compensation for activities with Bayer, Biogen Idec, Genzyme, Novartis, Teva Neuroscience, and Medimmune as an advisor. Dr. Broadley has nothing to disclose. Dr. Cabre has received personal compensation for activities with Biogen Idec, EMD Serono, and Novartis. Dr. Han has nothing to disclose. Dr. Jacob has nothing to disclose. Dr. John has received research support from Teva. Dr. Leite has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Nakashima has received personal compensation for activities with Bayer Schering Pharma, Novartis, and Biogen Idec. Dr. Nakashima has received research support from Mitsubishi Chemical Corporation. Dr. Palace has received personal compensation for activities with Novartis and Merck Serono. Dr. Schippling has received personal compensation for activities with Novartis. Dr. Schippling has received research support from Bayer Schering and Biogen Idec. Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corporation, EMD Serono, Teva Neuroscience, and Biogen Idec, Novartis, and Genzyme Corporation. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, and Mitsubishi Pharmaceuticals, MedImmune Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical, and Novartis. Dr. Weinshenker has received royalty pay Dr. Wingerchuk has received personal compensation for activities with Medimmune, Alexion, and Chugai. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.Wednesday, April 22 2015, 2:00 pm-6:30 pm